Literature DB >> 28580733

Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.

Juan Marquet1, Kyra Velazquez-Kennedy1, Sandra López1, Amparo Benito2, María-Jesús Blanchard3, Jose Antonio Garcia-Vela4.   

Abstract

Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Kaposi sarcoma; aggressive lymphoma; human herpesvirus 8; primary effusion lymphoma; valganciclovir

Mesh:

Substances:

Year:  2017        PMID: 28580733     DOI: 10.1002/hon.2445

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  5 in total

Review 1.  Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.

Authors:  Donal McHugh; Nicole Caduff; Anita Murer; Christine Engelmann; Yun Deng; Hana Zdimerova; Kyra Zens; Obinna Chijioke; Christian Münz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

2.  Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Authors:  J Chen; V Mehraj; J Szabo; B Routy; R P Michel; J P Routy
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 3.  Primary effusion lymphoma: current perspectives.

Authors:  Mayur Narkhede; Shagun Arora; Chaitra Ujjani
Journal:  Onco Targets Ther       Date:  2018-06-28       Impact factor: 4.147

4.  [Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].

Authors:  Y F Song; H Liu; J F Bai; H X Ke; J T Li; T Wang; Y Z Yang; J J Yin; R Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 5.  Primary Effusion Lymphoma: A Clinicopathologic Perspective.

Authors:  Diamone A Gathers; Emily Galloway; Katalin Kelemen; Allison Rosenthal; Sarah E Gibson; Javier Munoz
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.